FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310112156> ?p ?o ?g. }

• W4310112156 endingPage "10070" @default.
• W4310112156 startingPage "10068" @default.
• W4310112156 abstract "BACKGROUND In 2014, the International Myeloma Working Group (IMWG) revised the Renal involvement of the CRAB (hyperCalcemia, Renal, Anemia, Bone lesions) criteria for the diagnosis of multiple myeloma (MM) as an acute decline in kidney function represented by either a serum creatinine (Scr) > 2 mg/dl or an estimated glomerular filtration rate of < 40 ml/min/1.73 m2 secondary to light chain cast nephropathy (LCCN) biopsy proven or suspected. Since LCCN occurs only in patients with high serum free light chain (FLC) levels, a high tumor burden is presumed but how often it occurs with other myeloma defining events (MDE) is unknown. METHODS Patients were selected from 2 cohorts. The first cohort came from a multicenter study on LCCN who were all diagnosed with MM between 2000 and 2018. Only newly diagnosed patients were included in this study. A second cohort was identified from the Mayo Clinic Kidney Biopsy database from 2003 to 2013. Inclusion criteria of this cohort were: the LCCN must be the dominate pathology on the kidney biopsy and it is secondary to a plasma cell proliferative disorder. Laboratory and radiologic data were collected to assess for CRAB criteria. Bone lesions were assessed by standard skeletal X-ray, MRI or CT/PET. Most had skeletal X-ray. The new SLiM CRAB criteria which have the addition 3 biomarkers: (S) >60% bone marrow plasma cells, (Li) an involved to uninvolved free light chain (FLC) ratio > 100 and (M) >1 bone lesion on MRI were also assessed. RESULTS From the multicenter study, 28 patients were excluded for having relapsed MM and 27 were from Mayo who were included in the second cohort leaving 123 patients. In the Mayo cohort, 52 patients were identified who met criteria. Both cohorts were comparable in age, sex, bone marrow plasma cells and hemoglobin at diagnosis (Table 1). Interestingly, 3.3% of the multicenter cohort and 3.9% of the Mayo cohort did not meet the R criterion due to a presenting creatinine of ≤ 2.0 mg/dl. In the multicenter cohort 2/99 (2.0%) and 4/52 (7.7%) of the Mayo cohort had < 10% bone marrow plasma cells. The presenting involved FLC was higher in the multicenter group (p = 0.001). In the multicenter cohort, 99.1% met at least one of the SLiM criteria and 84.7% met one the C,A,B criteria. In the Mayo cohort, fewer patients met at least one of the SLiM criteria (86.5%, p < 0.001) but more patients met one or more of the C,A,B criteria (98.1%, p = 0.01). All but 1 patient from the multicenter cohort met one or more of the SliM C,A,B criteria. The most common SLiM criteria met in the multicenter cohort was Li while it was M in the Mayo cohort. The most common C,A,B criteria in the multicenter cohort was A while it was B in the Mayo cohort. DISCUSSION This study provides the first evidence that nearly all patients who present with biopsy proven LCCN have at least one other MDE. Bone marrow burden was met in 98.0% of the multicenter cohort where all patients were diagnosed with MM, 92.3% of the Mayo cohort where the diagnosis of MM was not a prerequisite. More importantly, 84.7% and 98.1% of patients from the 2 cohorts respectively had another MDE besides LCCN confirming that LCCN is associated with high tumor burden. All but 1 patient would have been diagnosed with MM based on the SLiM CRAB criteria. In comparison to patients with other kidney lesions associated with monoclonal immunoglobulin, generally only 20-30% met the CRAB criteria for MM. This is why it is more appropriate to classify those patients as having monoclonal gammopathy of renal significance while patients with LCCN should be diagnosed with MM. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310112156 created "2022-11-30" @default.
• W4310112156 creator A5000308170 @default.
• W4310112156 creator A5001453763 @default.
• W4310112156 creator A5001851529 @default.
• W4310112156 creator A5002248011 @default.
• W4310112156 creator A5007192014 @default.
• W4310112156 creator A5007747233 @default.
• W4310112156 creator A5012705049 @default.
• W4310112156 creator A5016610534 @default.
• W4310112156 creator A5016853434 @default.
• W4310112156 creator A5020591775 @default.
• W4310112156 creator A5022179123 @default.
• W4310112156 creator A5023193953 @default.
• W4310112156 creator A5025976062 @default.
• W4310112156 creator A5026574827 @default.
• W4310112156 creator A5029802364 @default.
• W4310112156 creator A5033220547 @default.
• W4310112156 creator A5035070160 @default.
• W4310112156 creator A5037323115 @default.
• W4310112156 creator A5038404580 @default.
• W4310112156 creator A5042275995 @default.
• W4310112156 creator A5054957898 @default.
• W4310112156 creator A5055007613 @default.
• W4310112156 creator A5055410111 @default.
• W4310112156 creator A5056020540 @default.
• W4310112156 creator A5056260546 @default.
• W4310112156 creator A5068637846 @default.
• W4310112156 creator A5074505099 @default.
• W4310112156 creator A5076611748 @default.
• W4310112156 creator A5076920874 @default.
• W4310112156 creator A5077686486 @default.
• W4310112156 creator A5080390622 @default.
• W4310112156 creator A5084214896 @default.
• W4310112156 creator A5086035399 @default.
• W4310112156 creator A5086608494 @default.
• W4310112156 creator A5091408535 @default.
• W4310112156 creator A5091901169 @default.
• W4310112156 date "2022-11-15" @default.
• W4310112156 modified "2023-10-01" @default.
• W4310112156 title "Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event" @default.
• W4310112156 doi "https://doi.org/10.1182/blood-2022-162754" @default.
• W4310112156 hasPublicationYear "2022" @default.
• W4310112156 type Work @default.
• W4310112156 citedByCount "0" @default.
• W4310112156 crossrefType "journal-article" @default.
• W4310112156 hasAuthorship W4310112156A5000308170 @default.
• W4310112156 hasAuthorship W4310112156A5001453763 @default.
• W4310112156 hasAuthorship W4310112156A5001851529 @default.
• W4310112156 hasAuthorship W4310112156A5002248011 @default.
• W4310112156 hasAuthorship W4310112156A5007192014 @default.
• W4310112156 hasAuthorship W4310112156A5007747233 @default.
• W4310112156 hasAuthorship W4310112156A5012705049 @default.
• W4310112156 hasAuthorship W4310112156A5016610534 @default.
• W4310112156 hasAuthorship W4310112156A5016853434 @default.
• W4310112156 hasAuthorship W4310112156A5020591775 @default.
• W4310112156 hasAuthorship W4310112156A5022179123 @default.
• W4310112156 hasAuthorship W4310112156A5023193953 @default.
• W4310112156 hasAuthorship W4310112156A5025976062 @default.
• W4310112156 hasAuthorship W4310112156A5026574827 @default.
• W4310112156 hasAuthorship W4310112156A5029802364 @default.
• W4310112156 hasAuthorship W4310112156A5033220547 @default.
• W4310112156 hasAuthorship W4310112156A5035070160 @default.
• W4310112156 hasAuthorship W4310112156A5037323115 @default.
• W4310112156 hasAuthorship W4310112156A5038404580 @default.
• W4310112156 hasAuthorship W4310112156A5042275995 @default.
• W4310112156 hasAuthorship W4310112156A5054957898 @default.
• W4310112156 hasAuthorship W4310112156A5055007613 @default.
• W4310112156 hasAuthorship W4310112156A5055410111 @default.
• W4310112156 hasAuthorship W4310112156A5056020540 @default.
• W4310112156 hasAuthorship W4310112156A5056260546 @default.
• W4310112156 hasAuthorship W4310112156A5068637846 @default.
• W4310112156 hasAuthorship W4310112156A5074505099 @default.
• W4310112156 hasAuthorship W4310112156A5076611748 @default.
• W4310112156 hasAuthorship W4310112156A5076920874 @default.
• W4310112156 hasAuthorship W4310112156A5077686486 @default.
• W4310112156 hasAuthorship W4310112156A5080390622 @default.
• W4310112156 hasAuthorship W4310112156A5084214896 @default.
• W4310112156 hasAuthorship W4310112156A5086035399 @default.
• W4310112156 hasAuthorship W4310112156A5086608494 @default.
• W4310112156 hasAuthorship W4310112156A5091408535 @default.
• W4310112156 hasAuthorship W4310112156A5091901169 @default.
• W4310112156 hasBestOaLocation W43101121561 @default.
• W4310112156 hasConcept C121332964 @default.
• W4310112156 hasConcept C126322002 @default.
• W4310112156 hasConcept C134018914 @default.
• W4310112156 hasConcept C159654299 @default.
• W4310112156 hasConcept C203014093 @default.
• W4310112156 hasConcept C2776364478 @default.
• W4310112156 hasConcept C2779662365 @default.
• W4310112156 hasConcept C2781184683 @default.
• W4310112156 hasConcept C36394416 @default.
• W4310112156 hasConcept C502942594 @default.
• W4310112156 hasConcept C555293320 @default.
• W4310112156 hasConcept C62520636 @default.
• W4310112156 hasConcept C71924100 @default.
• W4310112156 hasConceptScore W4310112156C121332964 @default.
• W4310112156 hasConceptScore W4310112156C126322002 @default.

• next